Two phase III studies evaluate the use of combination verteporfin photodynamic therapy with ranibizumab for subfoveal choroidal neovascularisation secondary to AMD

Source: Ophthalmology
Area: News
According to the results of two phase III studies published in Ophthalmology, the addition of verteporfin photodynamic therapy (PDT) to ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularisation secondary to age-related macular degeneration (AMD).   The first study (MONT BLANC), compared the efficacy and safety of same-day verteporfin PDT and intravitreal ranibizumab combination treatment versus ranibizumab monotherapy in neovascular age-related macular degeneration.   The prospective, double-blind, randomised, active-controlled trial involved 255 patients with all types of active subfoveal choroidal neovascularisation. Patients (Read more...)

Full Story →